Premium
Design, Synthesis, Antibacterial Evaluation and Docking Study of Novel 2‐Hydroxy‐3‐(nitroimidazolyl)‐propyl‐derived Quinolone
Author(s) -
Li Qing,
Xing Junhao,
Cheng Haibo,
Wang Hui,
Wang Jing,
Wang Shuai,
Zhou Jinpei,
Zhang Huibin
Publication year - 2015
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12395
Subject(s) - gatifloxacin , antibacterial activity , chemistry , docking (animal) , moxifloxacin , quinolone , stereochemistry , minimum inhibitory concentration , in vitro , staphylococcus epidermidis , levofloxacin , antibiotics , staphylococcus aureus , biochemistry , biology , bacteria , medicine , nursing , genetics
A novel series of 2‐hydroxy‐3‐(nitroimidazolyl)‐propyl‐derived quinolones 6a – o were synthesized and evaluated for their in vitro antibacterial activity. Most of the target compounds exhibited potent activity against Gram‐positive strains. Among them, moxifloxacin analog 6n displayed the most potent activity against Gram‐positive strains including S. epidermidis (MIC = 0.06 μ g/mL), MSSE (MIC = 0.125 μ g/mL), MRSE (MIC = 0.03 μ g/mL), S. aureus (MIC = 0.125 μ g/mL), MSSA (MIC = 0.125 μ g/mL), (MIC = 2 μ g/mL). Its activity against MRSA was eightfold more potent than reference drug gatifloxacin. Finally, docking study of the target compound 6n revealed that the binding model of quinolone nucleus was similar to that of gatifloxacin and the 2‐hydroxy‐3‐(nitroimidazolyl)‐propyl group formed two additional hydrogen bonds.